Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

BACKGROUND: First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenehjem, David D., Hahn, Andrew W., Gill, David M., Albertson, Daniel, Gowrishankar, Banumathy, Merriman, Joseph, Agarwal, Archana M., Thodima, Venkata, Harrington, Erik B., Au, Trang H., Maughan, Benjamin L., Houldsworth, Jane, Pal, Sumanta K., Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347137/
https://www.ncbi.nlm.nih.gov/pubmed/30682039
http://dx.doi.org/10.1371/journal.pone.0210415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347137/
https://www.ncbi.nlm.nih.gov/pubmed/30682039
http://dx.doi.org/10.1371/journal.pone.0210415

Ejemplares similares